

1 TO THE HONORABLE SENATE:

2 The Committee on Health and Welfare to which was referred House Bill  
3 No. 611 entitled “An act relating to miscellaneous provisions affecting the  
4 Department of Vermont Health Access” respectfully reports that it has  
5 considered the same and recommends that the Senate propose to the House that  
6 the bill be amended as follows:

7 First: By striking out Sec. 2, 18 V.S.A. § 4682, in its entirety and inserting  
8 in lieu thereof a new Sec. 2 to read as follows:

9 Sec. 2. 18 V.S.A. § 4682 is amended to read:

10 § 4682. DISCRIMINATION AGAINST 340B ENTITIES PROHIBITED

11 \* \* \*

12 (b) A manufacturer or its agent shall not directly or indirectly require a  
13 340B covered entity to submit any claims, utilization, encounter, purchase, or  
14 other data as a condition for allowing the acquisition of a 340B drug by or  
15 delivery of a 340B drug to a 340B contract pharmacy or a 340B covered entity  
16 unless the claims or utilization data sharing is required by the U.S. Department  
17 of Health and Human Services.

18 \* \* \*

19 (d) ~~A manufacturer or its agent shall offer or otherwise make available~~  
20 ~~340B drug pricing to a 340B covered entity or 340B contract pharmacy in the~~

1 ~~form of a discount at the time of purchase and shall not offer or otherwise~~  
2 ~~make available 340B drug pricing in the form of a rebate. [Repealed.]~~

3 Second: In Sec. 9, amending 2025 Acts and Resolves No. 50, Sec. 8, in  
4 subsection (a), by striking out “2026” both times it appears and inserting in  
5 lieu thereof “~~2026~~ 2027”

6 **Third: By adding a new section to be Sec. 9a to read as follows:**

7 **Sec. 9a. DEPARTMENT OF FINANCIAL REGULATION; ANALYSIS OF**  
8 **GLP-1 DRUG COVERAGE REQUIREMENT; REPORT**

9 **On or before January 15, 2027, the Department of Financial Regulation**  
10 **shall report to the House Committee on Health Care and the Senate**  
11 **Committees on Health and Welfare and on Finance on the estimated**  
12 **amount that health insurance premiums would increase if Vermont were**  
13 **to enact legislation requiring health insurance plans to cover glucagon-like**  
14 **peptide-1 (GLP-1) receptor agonist medications for all U.S. Food and**  
15 **Drug Administration–approved indications, including the amounts of the**  
16 **State’s financial obligations for defrayal of premium increases for**  
17 **qualified health benefit plans pursuant to 45 C.F.R. § 155.170 and for**  
18 **premium increases in the State Employees’ Health Benefit Plan.**

19  
20  
21

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13

(Committee vote: \_\_\_\_\_)

\_\_\_\_\_

Senator \_\_\_\_\_

FOR THE COMMITTEE